Incyte Corporation (INCY) Stake Boosted by Gotham Asset Management LLC

Gotham Asset Management LLC increased its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 37.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,454 shares of the biopharmaceutical company’s stock after purchasing an additional 19,048 shares during the period. Gotham Asset Management LLC’s holdings in Incyte Corporation were worth $8,871,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in INCY. US Bancorp DE lifted its holdings in shares of Incyte Corporation by 67.1% during the 1st quarter. US Bancorp DE now owns 2,931 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 1,177 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Incyte Corporation by 21.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 6,188 shares of the biopharmaceutical company’s stock valued at $827,000 after purchasing an additional 1,073 shares in the last quarter. Municipal Employees Retirement System of Michigan bought a new position in shares of Incyte Corporation during the 1st quarter valued at about $755,000. Redwood Investments LLC bought a new position in shares of Incyte Corporation during the 1st quarter valued at about $1,040,000. Finally, Bellevue Group AG lifted its holdings in shares of Incyte Corporation by 24.3% during the 1st quarter. Bellevue Group AG now owns 186,950 shares of the biopharmaceutical company’s stock valued at $24,990,000 after purchasing an additional 36,550 shares in the last quarter. Institutional investors and hedge funds own 88.91% of the company’s stock.

In related news, President Herve Hoppenot sold 70,502 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $119.45, for a total transaction of $8,421,463.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Barry P. Flannelly sold 714 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $124.25, for a total value of $88,714.50. Following the sale, the executive vice president now directly owns 15,496 shares of the company’s stock, valued at $1,925,378. The disclosure for this sale can be found here. Insiders have sold 109,452 shares of company stock valued at $13,707,134 over the last ninety days. 17.70% of the stock is currently owned by company insiders.

WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/09/incyte-corporation-incy-stake-boosted-by-gotham-asset-management-llc.html.

Incyte Corporation (NASDAQ INCY) traded down 0.03% on Monday, hitting $114.67. The company had a trading volume of 133,838 shares. The stock has a 50 day moving average of $121.38 and a 200-day moving average of $127.20. The stock’s market capitalization is $23.59 billion. Incyte Corporation has a one year low of $83.01 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $326.40 million for the quarter, compared to analysts’ expectations of $318.45 million. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The business’s revenue was up 32.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.18 earnings per share. Equities analysts anticipate that Incyte Corporation will post ($0.83) EPS for the current year.

INCY has been the topic of a number of recent research reports. J P Morgan Chase & Co set a $149.00 target price on Incyte Corporation and gave the company a “buy” rating in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 target price on shares of Incyte Corporation in a research report on Thursday, July 27th. Gabelli reissued a “buy” rating and issued a $174.00 target price on shares of Incyte Corporation in a research report on Wednesday, June 28th. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 target price (down previously from $172.00) on shares of Incyte Corporation in a research report on Monday, September 11th. Finally, Cowen and Company reissued an R

Several other large investors have also added to or reduced their stakes in INCY. US Bancorp DE lifted its holdings in shares of Incyte Corporation by 67.1% during the 1st quarter. US Bancorp DE now owns 2,931 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 1,177 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Incyte Corporation by 21.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 6,188 shares of the biopharmaceutical company’s stock valued at $827,000 after purchasing an additional 1,073 shares in the last quarter. Municipal Employees Retirement System of Michigan bought a new position in shares of Incyte Corporation during the 1st quarter valued at about $755,000. Redwood Investments LLC bought a new position in shares of Incyte Corporation during the 1st quarter valued at about $1,040,000. Finally, Bellevue Group AG lifted its holdings in shares of Incyte Corporation by 24.3% during the 1st quarter. Bellevue Group AG now owns 186,950 shares of the biopharmaceutical company’s stock valued at $24,990,000 after purchasing an additional 36,550 shares in the last quarter. Institutional investors and hedge funds own 88.91% of the company’s stock.

In related news, President Herve Hoppenot sold 70,502 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $119.45, for a total transaction of $8,421,463.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Barry P. Flannelly sold 714 shares of the stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $124.25, for a total value of $88,714.50. Following the sale, the executive vice president now directly owns 15,496 shares of the company’s stock, valued at $1,925,378. The disclosure for this sale can be found here. Insiders have sold 109,452 shares of company stock valued at $13,707,134 over the last ninety days. 17.70% of the stock is currently owned by company insiders.

WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/09/incyte-corporation-incy-stake-boosted-by-gotham-asset-management-llc.html.

Incyte Corporation (NASDAQ INCY) traded down 0.03% on Monday, hitting $114.67. The company had a trading volume of 133,838 shares. The stock has a 50 day moving average of $121.38 and a 200-day moving average of $127.20. The stock’s market capitalization is $23.59 billion. Incyte Corporation has a one year low of $83.01 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01). The business had revenue of $326.40 million for the quarter, compared to analysts’ expectations of $318.45 million. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The business’s revenue was up 32.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.18 earnings per share. Equities analysts anticipate that Incyte Corporation will post ($0.83) EPS for the current year.

INCY has been the topic of a number of recent research reports. J P Morgan Chase & Co set a $149.00 target price on Incyte Corporation and gave the company a “buy” rating in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 target price on shares of Incyte Corporation in a research report on Thursday, July 27th. Gabelli reissued a “buy” rating and issued a $174.00 target price on shares of Incyte Corporation in a research report on Wednesday, June 28th. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 target price (down previously from $172.00) on shares of Incyte Corporation in a research report on Monday, September 11th. Finally, Cowen and Company reissued an “outperform” rating and issued a $130.00 target price on shares of Incyte Corporation in a research report on Monday, July 3rd. Seven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $144.84.

Incyte Corporation Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply